SK
Samuel K. (Sam) Ruch
Executive Vice President, General Counsel, and Corporate Secretary
Puma BiotechnologyTherapeutic Areas
Puma Biotechnology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NERLYNX® (neratinib, oral) | HER2-positive early-stage breast cancer (extended adjuvant) | Approved |
| NERLYNX® (neratinib) | HER2-positive metastatic breast cancer | Approved/Commercial |
| Alisertib | Small Cell Lung Cancer (SCLC) | Phase 2 |
| PB272 (neratinib, intravenous) | Cancer | Not Disclosed |
| PB357 | Cancer | Not Disclosed |
Leadership Team at Puma Biotechnology
AH
Alan H. Auerbach
Chief Executive Officer, President, and Chairman of the Board
RJ
Robert J. (Bob) LaCaze
Executive Vice President and Chief Commercial Officer
BA
Brian A. Leyland-Jones
Chief Medical Officer
JP
James P. (Jim) O'Brien
Executive Vice President and Chief Financial Officer